• Get inspired by peer-reviewed publications of our scientists, partners, and customers around the globe.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

MIMETAS raises 5.2 million dollar for organ-on-a-chip

New funding opens doors to become a global leader in Organ-on-a-Chip

Leiden, the Netherlands, October 8, 2014. MIMETAS B.V. announces that it has raised 5.2 million dollars to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners to fund the development and sales of MIMETAS’ unique 3D disease- and tissue modeling technologies.

Jos Joore, co-founder and Chief Business Officer of MIMETAS, acknowledges that these resources arrive at a strategically important moment: “Collaborations with top-tier pharmaceutical companies are expanding rapidly, an example of this is the recently announced 1.6 million dollar kidney-on-a-chip project with Roche, Pfizer and GlaxoSmithKline. The funds will be used to scale up the production of OrganoPlates™ and strengthen our activities in predictive preclinical model development, thus consolidating our leadership in this highly competitive field.”

Currently, MIMETAS has a range of disease-, toxicology- and ADME models in her pipeline, in various stages of development and validation.

“We immediately recognized MIMETAS’ large upside potential”, says Johan Sebregts, managing director of ZIF, “To help developing this, we support MIMETAS not only with capital, but also through the vast expertise of our shareholders that include Dutch captains of industry”.

Marius Prins, CEO of PPM Oost, who is also very pleased with the investment in MIMETAS, states: “Significant value creation through better disease models with reduced laboratory animal use is highly relevant to our fund. In addition, this strategic investment helps us to pair two top technology clusters in the Netherlands in one thriving enterprise: biotechnology at the Leiden Bioscience Park and microfluidics at Twente University.”

About PPM Oost
Participatiemaatschappij Oost Nederland NV (PPM Oost) invests in promising companies that contribute to a flourishing economy in the East Netherlands. PPM Oost has invested in over 195 companies with a total fund size of more than € 250 million under management.

About ZIF
Zeeuws InvesteringsFonds (ZIF) was founded by six private investors in collaboration with Development Agency “NV Economische Impuls” and the ZIGZAG Foundation. ZIF invests in technology companies in the seed stage. In addition to investing capital, ZIF invests by contributing knowledge, network, and experience of its shareholders and the fund management.


‘May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy

Accept all
Accept selected
Decline all